Cannabigerol Oil for Adolescents With ADHD (CAN-ADHD)

Recruiting now · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Attention-Deficit/Hyperactivity Disorder (ADHD)

In brief

This study aims to evaluate the potential effects of full-spectrum cannabigerol (CBG) oil on cognitive and behavioral symptoms in adolescents diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD). ADHD is a neurodevelopmental disorder characterized by inattention, hyperactivity, and impulsivity, often associated with impairments in academic, social, and emotional functioning. This is a randomized, double-blind, placebo-controlled clinical trial with a parallel design. A total of 60 adolescents aged 12 to 17 years, diagnosed with ADHD and with insufficient response to previous treatments, will be enrolled and randomly assigned to either the intervention group or the placebo group. Participants in the intervention group will receive full-spectrum CBG oil (30 mg/mL), administered sublingually, with individualized dosing determined by the study physician and adjusted through weekly monitoring. The placebo group will receive an inert oil matched in appearance and administration conditions. The intervention will last for 12 weeks, including in-person clinical assessments at baseline, week 6, and week 12, as well as weekly remote monitoring to assess adherence, safety, and dose adjustments. Primary outcomes will include changes in ADHD symptom severity measured by the SNAP-IV scale. Secondary outcomes will assess quality of life, emotional symptoms, sleep patterns, and safety profile. This study aims to contribute to the scientific understanding of cannabinoids as a potential therapeutic option for adolescents with ADHD, a population for which current evidence remains limited.

Key facts

Study ID

NCT07592390

Run by

Universidade do Sul de Santa Catarina

People needed

60

Starts

2026-05-01

Expected to finish

2026-12-18

Last updated by the study team

2026-05-18

Who can join

Age: 12 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adolescents aged 12 to 17 years
• Diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD) confirmed using the SNAP-IV (Swanson, Nolan and Pelham Questionnaire, version IV)
• History of previous treatment with pharmacological or non-pharmacological interventions without significant improvement of symptoms
• Absence of severe psychiatric disorders or relevant physical comorbidities
• Ability of the participant and legal guardian to understand study procedures
• Provision of written informed consent by the legal guardian and assent by the adolescent

You may not qualify if…

• Use of cannabinoid-based substances (natural or synthetic) within 30 days prior to study initiation
• History of intolerance or adverse reactions to cannabis-derived compounds (e.g., confusion, paranoia, pruritus, excessive drowsiness, vomiting, diarrhea, or seizures)
• Presence of any significant physical comorbidity
• Presence of severe psychiatric disorder not related to ADHD
• Moderate to severe cognitive impairment
• Inability or unwillingness to complete study procedures or questionnaires adequately

Where it is running

• Universidade do Sul de Santa Catarina - UNISUL — Tubarão, Santa Catarina, Brazil (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.